Logo

Fluidigm: Ana Stankovic

Dec 16, 2020

Fluidigm has appointed Ana Stankovic to its board of directors. Stankovic is currently managing partner at Koliada Consulting, a firm focused on biotech, medical devices, and in vitro diagnostics. Previously, she was senior vice president for worldwide regional medical affairs and global health at Becton Dickinson. She served in senior roles at BD for more than a decade, leading medical affairs and clincal operations for various BD units. Prior to this, Stankovic was an associate clinical professor in the Department of Pathology, Microbiology, and Immunology at Vanderbilt University School of Medicine. She also served for two years as a guest lecturer in the Department of Pathology at Harvard Medical School, and is a former chief resident in the Department of Pathology at the University of Alabama at Birmingham.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.